Boston Scientific has received FDA approval of its INCEPTA, ENERGEN and PUNCTUA cardiac resynchronization therapy defibrillators (CRT-Ds) and implantable cardioverter defibrillators (ICDs) to treat heart failure and sudden cardiac death. The devices feature a new connector system, the 4-SITE DF4, which reduces volume and keeps a thickness of less than 10mm, according to Boston Scientific making them the smallest ones currently on the market.
The new connector combines three separate lead terminals into one integrated connection, simplifying and shortening implantation and lead connection. The 4-SITE lead was based on the RELIANCE family of defibrillation leads. The devices integrate with the LATITUDE Patient Management system, which allows for remote monitoring of ICD and CRT-D device patients and which may also be connected to a weight scale and blood pressure cuff sensors from the company.